Joint Analyst Price Targets - Benzinga

The Joint Corp

JYNTNASDAQ

Trade with Public

Trade with Public

$7.03

0.121.74%

Últ. Act.: Oct 16, 4:00 PM

$7.03

0.121.74%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Politica de privacidad
Terms of Use
Accessibility

Joint Analyst Price Targets

Wall Street analyst price targets and consensus rating for Joint (JYNT).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$17Upside to Avg. PT+145.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 8, 2025	B. Riley Securities	Jeff Van Sinderen	PT Cut	Buy	$20→$18
May 9, 2025	Lake Street	Ryan Meyers	PT Cut	Buy	$20→$16
Nov 8, 2024	Roth MKM	George Kelly	PT Cut	Buy	$16→$15
Aug 9, 2024	Lake Street	Brooks O'Neil	PT Raise	Buy	$15→$20
May 6, 2024	B. Riley Securities	Jeff Van Sinderen	PT Raise	Buy	$12→$20
May 3, 2024	Roth MKM	George Kelly	PT Raise	Buy	$13→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Joint, Lowers Price Target to $18

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Joint, Lowers Price Target to $16

Lake Street analyst Ryan Meyers maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $20 to $16.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Joint, Lowers Price Target to $15

Roth MKM analyst George Kelly maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $16 to $15.

Benzinga Newsdesk

Quest Diagnostics to Expand in Canada With LifeLabs Buyout

Quest Diagnostics (NYSE: DGX) has entered into a definitive agreement with OMERS to acquire LifeLabs, a prominent Canadian provider of community laboratory tests.

Zacks

Neuronetics Expands NeuroStar Portfolio With New Launch

Neuronetics, Inc. (NASDAQ: STIM) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company's NeuroStar product line.

Zacks

PRO
B. Riley Securities Maintains Buy on Joint, Raises Price Target to $20

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:JYNT) with a Buy and raises the price target from $12 to $20.

Benzinga Newsdesk